Regionalization of cardiac surgery in the United States and Canada. Geographic access, choice, and outcomes

JAMA ◽  
1995 ◽  
Vol 274 (16) ◽  
pp. 1282-1288 ◽  
Author(s):  
K. Grumbach
2021 ◽  
pp. 088506662110668
Author(s):  
Asha Singh ◽  
Chen Liang ◽  
Stephanie L. Mick ◽  
Chiedozie Udeh

Background The Cardiac Surgery Score (CASUS) was developed to assist in predicting post-cardiac surgery mortality using parameters measured in the intensive care unit. It is calculated by assigning points to ten physiologic variables and adding them to obtain a score (additive CASUS), or by logistic regression to weight the variables and estimate the probability of mortality (logistic CASUS). Both additive and logistic CASUS have been externally validated elsewhere, but not yet in the United States of America (USA). This study aims to validate CASUS in a quaternary hospital in the USA and compare the predictive performance of additive to logistic CASUS in this setting. Methods Additive and logistic CASUS (postoperative days 1-5) were calculated for 7098 patients at Cleveland Clinic from January 2015 to February 2017. 30-day mortality data were abstracted from institutional records and the Death Registries for Ohio State and the Centers for Disease Control. Given a low event rate, model discrimination was assessed by area under the curve (AUROC), partial AUROC (pAUC), and average precision (AP). Calibration was assessed by curves and quantified using Harrell's Emax, and Integrated Calibration Index (ICI). Results 30-day mortality rate was 1.37%. For additive CASUS, odds ratio for mortality was 1.41 (1.35-1.46, P <0.001). Additive and logistic CASUS had comparable pAUC and AUROC (all >0.83). However, additive CASUS had greater AP, especially on postoperative day 1 (0.22 vs. 0.11). Additive CASUS had better calibration curves, and lower Emax, and ICI on all days. Conclusions Additive and logistic CASUS discriminated well for postoperative 30-day mortality in our quaternary center in the USA, however logistic CASUS under-predicted mortality in our cohort. Given its ease of calculation, and better predictive accuracy, additive CASUS may be the preferred model for postoperative use. Validation in more typical cardiac surgery centers in the USA is recommended.


Author(s):  
Rebecca R. Soares ◽  
Devayu Parikh ◽  
Charlotte N. Shields ◽  
Travis Peck ◽  
Anand Gopal ◽  
...  

Renal Failure ◽  
2009 ◽  
Vol 31 (8) ◽  
pp. 633-640 ◽  
Author(s):  
Susan M. Martinelli ◽  
Uptal D. Patel ◽  
Barbara G. Phillips-Bute ◽  
Carmelo A. Milano ◽  
Laura E. Archer ◽  
...  

2015 ◽  
Vol 139 (1) ◽  
pp. 206 ◽  
Author(s):  
D.I. Shalowitz ◽  
A.M. Vinograd ◽  
Giuntoli R.L.

Retina ◽  
2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Rebecca R. Soares ◽  
Louis Cai ◽  
Theodore Bowe ◽  
Annika Samuelson ◽  
Catherine Liu ◽  
...  

Author(s):  
E.A. Vail ◽  
M.-S. Shieh ◽  
H.B. Gershengorn ◽  
A.J. Walkey ◽  
P.K. Lindenauer ◽  
...  

PLoS ONE ◽  
2019 ◽  
Vol 14 (12) ◽  
pp. e0226750
Author(s):  
Mitali Stevens ◽  
Apeksha V. Shenoy ◽  
Sibyl H. Munson ◽  
Halit O. Yapici ◽  
Boye L. A. Gricar ◽  
...  

2010 ◽  
Vol 13 (11) ◽  
pp. 1331-1338 ◽  
Author(s):  
Melissa D.A. Carlson ◽  
Elizabeth H. Bradley ◽  
Qingling Du ◽  
R. Sean Morrison

Perfusion ◽  
2019 ◽  
Vol 34 (5) ◽  
pp. 417-421 ◽  
Author(s):  
Chris Oscier ◽  
Chinmay Patvardhan ◽  
Florian Falter ◽  
Will Tosh ◽  
John Dunning ◽  
...  

Central venoarterial extracorporeal membrane oxygenation has been used since the 1970s to support patients with cardiogenic shock following cardiac surgery. Despite this, in-hospital mortality is still high, and although rare, thrombus within the cardiac chambers or within the extracorporeal membrane oxygenation circuit is often fatal. Aprotinin is an antifibrinolytic available in Europe and Canada, though not currently in the United States. Due to historical safety concerns, use of aprotinin is generally limited and is commonly reserved for patients with the highest bleeding risk. Given the limited availability of aprotinin over the last decade, it is not surprising to find a complete absence of literature describing the use of venoarterial extracorporeal membrane oxygenation in the presence of aprotinin. We present three consecutive cases of rapid fatal intraoperative intracardiac thrombosis associated with post-cardiotomy central venoarterial extracorporeal membrane oxygenation in patients receiving aprotinin.


Sign in / Sign up

Export Citation Format

Share Document